Choose which categories of cookies you allow. Strictly necessary cookies are always on.
Required for core site functionality, security and your session. Always active.
Help us understand how visitors use the site (e.g. Google Analytics) so we can improve it.
Used to measure campaigns and show you relevant ads on other sites (e.g. LinkedIn, Google Ads).
Vortioxetine Market Analysis size 2021 was recorded $913.985 Million whereas by the end of 2025 it will reach $1314 Million. According to the author, by 2033 Vortioxetine market size will become $2715.87. Vortioxetine market will be growing at a CAGR of 9.5% during 2025 to 2033. Download a free sample with market size, key players, and regional forecast data verified by Supriya Yadav.
| Data Timeline | Historical Data: 2022–2025 | Base Year: 2025 | Forecast Period: 2026–2034 |
|---|---|
| type Segment | 5 Mg Tablets, 10 Mg Tablet, 15 Mg Tablet, 20 Mg Tablet |
| Application Segment | Depression, Generalized Anxiety Disorder, Attention Deficit Hyperactivity Disorder, Others |
| Distribution Channel Segment | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
|---|---|
| Age Group Segment | Children, Adult, Geriatric |
| Regions & Countries |
|
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| Global | $ 913.99 Million | $ 1314 Million | $ 2715.87 Million | 9.5% |
| North America | $ 290.65 Million | $ 413.13 Million | $ 835.87 Million | 9.208% |
| United States | $ 226.99 Million | $ 314.54 Million | $ 628.32 Million | 9.034% |
| Canada | $ 45.23 Million | $ 70.06 Million | $ 153.83 Million | 10.332% |
| Mexico | $ 18.44 Million | $ 28.53 Million | $ 53.72 Million | 8.231% |
| Europe | $ 262.31 Million | $ 372.29 Million | $ 736 Million | 8.893% |
| United Kingdom | $ 37.51 Million | $ 54.84 Million | $ 116.71 Million | 9.901% |
| France | $ 33.84 Million | $ 47.42 Million | $ 90.09 Million | 8.353% |
| Germany | $ 58.23 Million | $ 84.94 Million | $ 171.85 Million | 9.208% |
| Italy | $ 25.62 Million | $ 34.65 Million | $ 63.88 Million | 7.944% |
| Russia | $ 23.61 Million | $ 32.57 Million | $ 61.09 Million | 8.18% |
| Spain | $ 18.68 Million | $ 25.72 Million | $ 49.82 Million | 8.613% |
| Sweden | $ 13.89 Million | $ 19.4 Million | $ 38.03 Million | 8.779% |
| Denmark | $ 11.16 Million | $ 15.22 Million | $ 27.23 Million | 7.546% |
| Switzerland | $ 11.05 Million | $ 15.42 Million | $ 28.7 Million | 8.081% |
| Luxembourg | $ 9.91 Million | $ 13.89 Million | $ 25.02 Million | 7.636% |
| Rest of Europe | $ 18.81 Million | $ 28.23 Million | $ 63.58 Million | 10.683% |
| Asia Pacific | $ 197.42 Million | $ 291.26 Million | $ 625.78 Million | 10.032% |
| China | $ 69.49 Million | $ 102.03 Million | $ 215.39 Million | 9.789% |
| Japan | $ 39.13 Million | $ 56.98 Million | $ 115.96 Million | 9.288% |
| South Korea | $ 20.3 Million | $ 29.28 Million | $ 60.57 Million | 9.512% |
| India | $ 12.26 Million | $ 18.99 Million | $ 44.24 Million | 11.15% |
| Australia | $ 17.15 Million | $ 24.49 Million | $ 50.4 Million | 9.44% |
| Singapore | $ 8.49 Million | $ 12.03 Million | $ 25.28 Million | 9.726% |
| Taiwan | $ 6.71 Million | $ 10.19 Million | $ 24.41 Million | 11.53% |
| South East Asia | $ 13.69 Million | $ 20.55 Million | $ 44.6 Million | 10.168% |
| Rest of APAC | xxxx | xxxx | xxxx | xxxx |
| South America | $ 61.24 Million | $ 86.27 Million | $ 168.38 Million | 8.719% |
| Brazil | $ 30.61 Million | $ 42.88 Million | $ 82.51 Million | 8.527% |
| Argentina | $ 8.25 Million | $ 11.69 Million | $ 23.41 Million | 9.068% |
| Colombia | $ 5.63 Million | $ 8.02 Million | $ 16.5 Million | 9.445% |
| Peru | $ 5.7 Million | $ 7.98 Million | $ 14.96 Million | 8.18% |
| Chile | $ 5.1 Million | $ 7.05 Million | $ 13.13 Million | 8.094% |
| Rest of South America | $ 5.94 Million | $ 8.67 Million | $ 17.87 Million | 9.47% |
| Middle East | $ 53.01 Million | $ 77.45 Million | $ 171.99 Million | 10.486% |
| Saudi Arabia | $ 14.58 Million | $ 21.69 Million | $ 50.96 Million | 11.267% |
| Turkey | $ 11.13 Million | $ 15.83 Million | $ 34.1 Million | 10.072% |
| UAE | $ 9.97 Million | $ 14.87 Million | $ 34.67 Million | 11.164% |
| Egypt | $ 6.47 Million | $ 9.27 Million | $ 20.14 Million | 10.189% |
| Qatar | $ 4.61 Million | $ 6.78 Million | $ 15.2 Million | 10.623% |
| Rest of Middle East | $ 6.26 Million | $ 9.03 Million | $ 16.92 Million | 8.171% |
| Africa | $ 49.36 Million | $ 73.6 Million | $ 177.85 Million | 11.661% |
| East Africa | xxxx | xxxx | xxxx | xxxx |
| West Africa | xxxx | xxxx | xxxx | xxxx |
| North Africa | xxxx | xxxx | xxxx | xxxx |
| South Africa | $ 12.39 Million | $ 19 Million | $ 47.87 Million | 12.244% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →How are Segments Performing in the Global Vortioxetine Market? Vortioxetine Market Type Segment Analysis According to Cognitive Market Research, 10 Mg Tablet stands out as the dominating category. The 10 mg dose is often regarded as an ideal equilibrium between effectiveness and the capacity to be tolerated. Furthermore, it offers enough therapeutic efficacy in the treatment of severe depressive illness while limiting adverse reactions. Therefore, both patients and healthcare professionals may favor this dose because of its efficacy. 20 Mg Tablet emerges as the fastest-growing category in the Vortioxetine Market. Due to the rising occurrence of serious mental health illnesses, there is a need for increased doses of therapies. Psychiatric diseases, including depression, anxiety disorders, bipolar disorder, and schizophrenia, are increasingly common on a worldwide scale.
Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.
To learn more about market share and segmentation, request the free sample pages.
The competitive landscape of the Vortioxetine market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. These organizations use various development tactics such as mergers, acquisitions, partnerships, cooperation, and product launches to broaden their customer base on a global scale.
September 2019: Lundbeck has declared its intention to purchase Alder BioPharmaceuticals at a price of $18 per share, resulting in a valuation of about $2 billion for Alder.
January 2020: Takeda has formed a research collaboration with the Massachusetts Institute of Technology (MIT) to accelerate advancements in artificial intelligence and healthcare. The MIT-Takeda Program is located in the MIT Jameel Clinic and is overseen by Professor James J. Collins. The program's steering committee is headed by Professor Anantha P. Chandrakasan, who serves as the dean of the MIT School of Engineering, and Anne Heatherington, the senior vice president and head of the Data Sciences Institute (DSI) at Takeda.
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| H.Lundbeck A/S | ••• | ••• | ••• | ••• |
| Takeda Pharmaceutical | ••• | ••• | ••• | ••• |
| Zydus Pharms | ••• | ••• | ••• | ••• |
| CSPC Ouyi Pharmaceutical | ••• | ••• | ••• | ••• |
| Simson Pharma Limited | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →The global Vortioxetine market is poised for substantial growth, driven by the increasing global prevalence of Major Depressive Disorder (MDD) and a growing emphasis on mental health. The drug's unique mechanism of action, which includes pro-cognitive benefits alongside its antidepressant effects, serves as a key differentiator in a crowded therapeutic landscape. This distinct clinical profile helps in capturing patient populations who experience cognitive dysfunction with depression. North America currently dominates the market, but the Asia-Pacific and African regions are projected to exhibit the fastest growth rates. This expansion is fueled by improving healthcare infrastructure, rising awareness, and increasing disposable incomes. However, the market faces significant challenges, primarily the impending patent expirations which will pave the way for generic competition and subsequent price erosion. Strategic life-cycle management and market expansion into untapped regions will be crucial for sustained growth.
To navigate the evolving market landscape, manufacturers should prioritize a multi-pronged strategy. Firstly, implement robust life-cycle management initiatives by investing in research for new indications or developing novel formulations (e.g., extended-release) to extend the product's value proposition. Secondly, accelerate geographic expansion into high-growth emerging markets like Africa (Nigeria, South Africa) and the Middle East (Saudi Arabia, UAE), which exhibit double-digit CAGRs. Thirdly, intensify marketing efforts focused on vortioxetine's unique pro-cognitive benefits to solidify brand differentiation against upcoming generics. Finally, engage proactively with payers and healthcare systems to establish value-based pricing models that reflect the drug's benefits on patient productivity and quality of life, securing favorable formulary placement post-patent expiry.
The Vortioxetine Market pertains to many issues associated with the antidepressant drug called vortioxetine. Vortioxetine is marketed under the brand names Trintellix and Brintellix. The precise method by which it operates is not fully understood, although it is hypothesized to elevate serotonin levels in the brain and maybe engage with certain serotonin receptors. Typical adverse effects include of nausea, vomiting, constipation, and sexual dysfunction. Potential severe adverse effects may include suicidal ideation (particularly in those below the age of 25), serotonin syndrome, hemorrhaging, manic episodes, and SIADH (syndrome of inappropriate antidiuretic hormone production). If the medicine is suddenly discontinued or the dosage is reduced, a withdrawal syndrome may manifest. It is typically not advisable to use during pregnancy and nursing.
For instance, in January 2024, Takeda Pharmaceutical Company Limited, a prominent market participant, has formed a cooperation with Protagonist to jointly develop and sell Rusfertide in the United States, with an equal share of earnings.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
★ Reviews
Rate this report
| type | 5 Mg Tablets, 10 Mg Tablet, 15 Mg Tablet, 20 Mg Tablet |
|---|---|
| Application | Depression, Generalized Anxiety Disorder, Attention Deficit Hyperactivity Disorder, Others |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| Age Group | Children, Adult, Geriatric |
| Conclusion | |
| List of Competitors | H.Lundbeck A/S, Takeda Pharmaceutical, Zydus Pharms, CSPC Ouyi Pharmaceutical, Simson Pharma Limited |
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Vortioxetine Market Analysis Market analysis.
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
The Vortioxetine Market pertains to many issues associated with the antidepressant drug called vortioxetine. Vortioxetine is marketed under the brand names Trintellix and Brintellix.
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Vortioxetine Market Analysis market.
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the vortioxetine market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
